Based in Marseille, France, immune biomarker expert HalioDx is at the forefront of Immuno-oncology diagnostics.
It offers tests to precisely measure immune reactions in and around a tumour, giving clinicians the ability to determine the severity of a patient’s disease and predict their response to treatment, regardless of the cancer stage or the molecular class.
They were developed thanks to the pioneering work of HalioDx co-founder Jerôme Galon and its INSERM team at the Centre de Recherche des Cordeliers in Paris. The company’s goal now is to play a leading role in partnering with academic and pharmaceutical industry to develop the immune contexture concept and deliver practical routine diagnostic tools to significantly impact therapy prescription for the benefit of patients.
They say: ‘We envision that the evaluation of the immune response to tumours will be the new diagnostic standard in Oncology:
- To guide existing treatment options, as the Immune contexture of tumours largely determines patients’ clinical outcome
- To guide the development of single and combined immunotherapies as clinical response is intimately dependent upon tumour immune microenvironment status.